UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012582
Receipt number R000010443
Scientific Title Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study
Date of disclosure of the study information 2013/12/15
Last modified on 2013/12/15 17:18:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study

Acronym

AABC study

Scientific Title

Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study

Scientific Title:Acronym

AABC study

Region

Japan


Condition

Condition

Normal tension glaucoma

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study was to evaluate the efficacy and safety of 0.1% brimonidine tartrate ophthalmic solution (0.1% brimonidine) preserved with sodium chlorite as add-on therapy in Japanese normal-tension glaucoma (NTG) patients who use prostaglandin analogues as first line therapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Efficacy
IOP value;IOP-lowering effect from baseline
(reduced value;reduction rate%)

Key secondary outcomes

Safety
1.Ocular safety assessment:
Conjunctival hyperemia,adverse events
2.Systemic safety assessment:
Blood pressure,the pulse,adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Added to 0.1% brimonidine tartrate ophthalmic solution for 3 months

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients under treatment with prostagrandine and/or beta blockers who are judged to require the addition of Brimonidine with be not able to achieve target IOP as on their current IOP lowering monotherapy.
2.On treatment IOPs of bilateral eyes were between 13 and 16 mmHg in at least three consecutive measurements without changing the prescription for three months or more; patients with an IOP of 10 to 12 mmHg were eligible if the central corneal thickness (CCT) was 470 micro meter or less.
3.Visual aquity is equall or more 0.5
4. Correction is under -10 diopter.

Key exclusion criteria

1.Complications with chronic or recurrent
uveitis,scleritis,or corneal herpes.
2.History of ocular trauma or intraocular
conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations.
3.Any abnormality preventing reliable
applanation tonometer in the study eye.
4.Known medical history of allergic to PGAs or beta-blockers.
5.Contraindication of betablockers.
6.Patients using an IOP-lowering drug other than those to be used in the study.
7.Patients using systemic administration of an oral CAI (Diamox,etc.).
8.Patient having serious eyes complications.
9.Women who are pregnant or lactating.
10.Severe dementia
11.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.

Target sample size

90


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Keiji Yoshikawa

Organization

Yoshikawa Eye Clinic

Division name

Ophthalmology Director

Zip code


Address

1-3-1 Nakamachi Machida-city Tokyo

TEL

042-739-0781

Email

keiyomd@ark.ocn.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toyoaki Tsumura

Organization

Fussa Hospital

Division name

Ophthalmology

Zip code


Address

1-6-1 Kamidaira Fussa-city Tokyo

TEL

042-551-1111

Homepage URL


Email

tsumura@fussahsp.jp


Sponsor or person

Institute

AABC study group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

公立福生病院(東京都)、吉川眼科クリニック(東京都)、中野総合病院(東京都)、上野眼科医院(東京都)、神楽坂みなみの眼科(東京都)、入間川病院(埼玉県)


Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 05 Month 17 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 17 Day

Last follow-up date

2013 Year 03 Month 14 Day

Date of closure to data entry

2013 Year 06 Month 30 Day

Date trial data considered complete

2013 Year 09 Month 15 Day

Date analysis concluded

2013 Year 10 Month 23 Day


Other

Other related information



Management information

Registered date

2013 Year 12 Month 15 Day

Last modified on

2013 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010443


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name